East Tennessee State University

Digital Commons @ East Tennessee State University
Undergraduate Honors Theses

Student Works

5-2017

Determination of the effects that a previously
uncharacterized secreted product from Klebsiella
pneumoniae has on Citrobacter freundii and
Enterobacter cloacae biofilms
Cody M. Hastings

Follow this and additional works at: https://dc.etsu.edu/honors
Part of the Bacteria Commons, Bacteriology Commons, Biological Phenomena, Cell
Phenomena, and Immunity Commons, Cell and Developmental Biology Commons, Medical Cell
Biology Commons, Medical Microbiology Commons, Microbial Physiology Commons, and the
Pathogenic Microbiology Commons
Recommended Citation
Hastings, Cody M., "Determination of the effects that a previously uncharacterized secreted product from Klebsiella pneumoniae has
on Citrobacter freundii and Enterobacter cloacae biofilms" (2017). Undergraduate Honors Theses. Paper 419. https://dc.etsu.edu/
honors/419

This Honors Thesis - Withheld is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University.
It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of Digital Commons @ East Tennessee State
University. For more information, please contact digilib@etsu.edu.

Determination of the effects that a previously uncharacterized secreted product
from Klebsiella pneumoniae has on Citrobacter freundii and Enterobacter cloacae
biofilms
By
Cody Hastings

An Undergraduate Thesis Submitted in Partial Fulfillment
of the Requirements for the
Honors-in-Discipline Human Health Program
College of Public Health
East Tennessee State University

Cody Hastings

Date

Dr. Sean J. Fox, Thesis Mentor

Date

Dr. Allan Forsman, Reader

Date

Dr. Anna Hiatt, Reader

Date

1

Contents
Abstract…………………………………………………………………….3
Introduction:
Bacterial Biofilms……………………………………………….4
Enterobacteriaceae………………………………………….…9
Secondary Metabolites……………………………………...12
Materials and Methods…………………………………………….15
Results and Discussion:
Attachment Phase Assays…..……………………….…….18
Maturation Phase Assays………………………………..…23
Zones of Inhibition……………………………………………27
Conclusions……………………………………………………………..29
Acknowledgements……………………………………………….…30
References………………………………………………………………31

2

Abstract
More so than ever, Multiple Drug Resistant (MDR) bacteria are on the rise
due to overuse of antibiotics along with natural selection for adaptations that
enhance drug-resistant properties. One particular bacterial family,
Enterobacteriaceae, has been problematic, exhibiting several bacterial members
that have developed a precipitous resistance to modern antibiotics and are also
primary causative agents of nosocomial, or hospital acquired, infections. Citrobacter
freundii (CF) and Enterobacter cloacae (ECL) are two species of the
Enterobacteriaceae family causing significant medical concern due to their role in
producing numerous opportunistic infections such as bacteremia, lower respiratory
tract infections, urinary tract infections, and endocarditis. Adding to the difficulty of
this situation is the ability of bacteria to produce biofilms. These biofilms are
communities of bacteria that exhibit increased resistance to antibiotic treatment
and eradication. Previous work in the laboratory of Dr. Fox at ETSU has identified
an uncharacterized product secreted by Klebsiella pneumoniae (KP), another
member of the Enterobacteriaceae family, which appears to have inhibitory effects
toward CF and ECL. The current study was designed to characterize the effects this
secreted product has on CF and ECL biofilms. Through a high throughput microtiter
plate assay, the effects of this secreted product were examined on CF and ECL
phases of biofilm attachment and maturation. Based on our findings, we have
concluded that this secreted product can be categorized as a possible bacteriostatic
agent against biofilm cell density, biofilm mass, and cell viability for both biofilm
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phases of attachment and maturation. These results demonstrate the potential for
future antimicrobial applications of this product for CF or ECL infected patients.

Introduction
Bacterial Biofilms
Microorganisms, much like humans, are subjected to the mechanisms of
evolution, such as natural selection. As such, over time, there have been many
diverse and unique adaptations developed among the microbial community. One
such way that bacteria has adapted to survive when conditions are less than
favorable is to mass together and form a slimy film on a wide variety of different
surfaces. We call this collaborative phenomenon biofilm production.
We can define a biofilm as an assemblage of microbial cells that is
irreversibly associated (cannot be removed by gentle rinsing) with a surface and
enclosed in a polymeric matrix [1]. Structurally, a biofilm consists of numerous
subunits, referred to as microcolonies. These microcolonies reside within a matrix
of extracellular polymeric substances (EPS) with a close proximity to each other.
This, in turn, provides the bacteria with an ideal environment for the creation of
nutrient gradients, gene exchange, and quorum sensing activities [1]. Biofilms are
amorphous and dynamic complexes that can also provide a community of bacteria
with adaptive resistance to antibiotics [2]. This aspect is especially important due to
the worrisome possibility that standard antibiotics that would typically inhibit or
kill bacteria in their planktonic, free-swimming state fail to have the same effect
once a biofilm is produced [3,4]. Also, when compared to free-swimming bacteria,
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biofilms are much better adapted to withstand adverse environmental conditions
such as nutrient deprivation, pH changes, oxygen radicals, and even biocides [5].
These adaptive benefits are only possible due to communities of bacteria joining
together to form coordinated and cooperative groups that, some say, appear
analogous to multicellular organisms [6].
The developed tolerance to antibiotics alone makes it easy to see the
evolutionary benefits of biofilm production. The communal setting of a biofilm
illustrates the capability of bacteria to function cooperatively and altruistically for
their survival. The results of this cooperation prove more efficacious for bacteria’s
prosperity than simply existing in a planktonic form. As such, these bacterial slime
layers are now everywhere. Biofilms have become ubiquitous in natural, industrial,
and most worryingly, clinical environments [7]. It is now accepted that, between
this ubiquitous nature of biofilms and estimates that approximately 90% of bacteria
exist in biofilms, living in groups is critical for a bacteria’s ecology and evolution
[5,6]. The general competition among bacteria, even of the same species, can often
result in a “kill or be killed” methodology. However, in biofilms, it is observed that
some bacteria within the biofilms decrease their own reproductive output in order
to increase the fitness of other cells. This can thereby benefit the biofilm community
as a whole rather than just an individual organism [6].
Bacteria are able to produce biofilms and subsequently work together as a
microbial community due to a secretion-detection mechanism called quorum
sensing (QS). The process of QS provides a mechanism for self-organization and
regulation of microbial cells. This involves an environmental sensing system that
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allows bacteria to monitor and respond to their own population densities [3]. Via
the production of diffusible organic signaling molecules, known as auto-inducers,
bacteria are able to communicate with each other at high enough population
densities to result in a change of gene expression [2,3].
Once the QS mediating signaling is achieved, the microbial community can
begin the process of biofilm production. At present, processes governing biofilm
formation that have been identified include: 1) the pre-conditioning of the adhesion
surface either by macromolecules present in the bulk liquid or intentionally coated
on the surface; 2) Transport of planktonic cells from the bulk liquid to the surface;
3) Adsorption of cells at the surface; 4) Desorption of reversibly adsorbed cells; 5)
Irreversible adsorption of bacterial cells at a surface; 6) Production of cell–cell
signaling molecules; 7) Transport of substrates to and within the biofilm; 8)
Substrate metabolism by the biofilm-bound cells and transport of products out of
the biofilm; and finally 9) Biofilm removal by detachment or sloughing [3].
Simplified, the process can be condensed to 4 main steps: preparation, attachment,
maturation, and dispersion. Depending on the bacteria, there are numerous
alterations or additions that can be made with each step as well as multiple
mechanisms that can aid the bacteria in achieving their optimal conditions for
biofilm production. For example, some bacteria have pili or other extracellular
filamentous appendages that aid in attachment [3] while others may rely on the
assistance of extracellular DNA or lipids to do the same [5].
It is worth revisiting that all of the processes mentioned above, from
attachment onward, are occurring embedded in an EPS comprised matrix.
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Proportionally in biofilms, the microorganisms account for less than 10% of the dry
mass, whereas the matrix can account for over 90% [3]. This conglomeration of
different biopolymers and water aids in the cohesion of the cells of the biofilm,
adhesion to the surface they are bound to, as well as diffusion of various bacterial
products [3,8]. Also, when the surrounding environment’s nutrients have been
depleted, there are enzymes produced by the bacteria of the biofilm that can break
down the biopolymers of the EPS. This provides the bacteria with immediate access
to carbon and energy sources when needed [8]. This mechanism of storage can
sustain a biofilm rather efficiently when considering the fact that 50-90% of biofilms
carbon contents resides in the EPS matrix [1].
The efficiency and resilience that biofilms provide bacteria illustrated thus
far effectively shows how they could be highly problematic in a clinical setting. In
recent years, there have been growing concerns about the ability of biofilms to
adhere and flourish within a patient, either on their internal natural body surfaces,
such as the mucosal epithelial linings for many of the body’s tracts, or on the abiotic
surfaces of indwelling medical devices (IMDs) [4]. With their adapted resistance to
many conventional antibiotic treatments, bacterial biofilms are able to survive the
standard treatments that physicians traditionally would use. As such, these biofilms
can eventually lead to clinical bacteremia or even chronic infection [2,4].
With the expanding research into the capability of biofilms to bind to internal
body surfaces, we are now able to identify multiple bacterial pathologies that owe
their persistence to biofilm formation. Biofilms have been linked as contributive
agents from something as simple as infection of a mild laceration to chronic
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inflammatory lung conditions, such as cystic fibrosis [5,7]. Other, more benign,
conditions such as urinary tract infections or middle ear infections can also have
biofilms contributing to their severity [4].
Due to the numerous resident bacteria within a biofilms’ constant exchange
of resistance plasmids, biofilm aggregates have greater genetic diversity than
standard planktonic bacteria. The secretion of endotoxin achieved by biofilm
bacteria aid in making them more virulent. Factor these facts in with the reduced
susceptibility to the antimicrobial agents that would traditionally eradicate the
planktonic form of the same bacteria, and the treatment of these otherwise brief
infections becomes much more difficult [1,7]. There has even been evidence to
support the claim that clinical biofilms can even acquire the ability to evade their
host’s own immune responses [1,2]. Thankfully, these infections are typically
confined to a single location, as the biofilm detaching from the surface it’s adhered
to would usually threaten its own prosperity [7].
In many ways, biofilm infection of IMDs is very similar to the situations as
described above. Wherever the device is located is where the biofilm will form and
similarly use the surrounding host environment to proliferate. Contrarily, with
biofilm infection on the abiotic surface of IMDs within a patient, the option of
removal is a perfectly viable treatment plan. This will typically be done in coupling
with systemic antibiotic therapy to ensure that any planktonic cells that detach
when the biofilm-infected device is extracted are eradicated before causing further
infection [4]. For some IMDs, such as urinary catheters, this treatment option is
both simple and effective seeing as how they can be easily removed. However, there

8

are IMDs, like dialysis fistulas or artificial heart valves that, if infected, can lead to
severe systemic bacteremia and be extremely expensive, not to mention dangerous,
to replace. The best viable approach to the treatment of biofilm-infected IMDs such
as these is a combination of surgical removal and antibiotic treatment, just like with
simple IMDs. However, these procedures can present much higher risks to the
patient and expenditures ranging from $15,000 to $50,000, depending on the IMD
and the invasiveness of the surgical procedure required [2,4].

Enterobacteriaceae
Of the known biofilm-producing bacteria relevant in both research and
clinical settings, there are numerous members belonging to the bacterial family
Enterobacteriaceae. Taxonomically, the bacterial family currently has 53 genera
and, of these, 26 are known to be associated with infections in humans [9].
Members of this family share numerous characteristics, such as being typically
small, gram negative, non-sporing, straight rods that are facultatively anaerobic and
grow well at standard human body temperature, 37℃ [9]. There are several
clinically significant members of this bacterial family that are causing concern in the
medical field, as their rapid adaptations outdo our current treatments. Between
their effectiveness and virulence as pathogens and their rapidly evolving tolerance
to the most powerful weapons in our antibiotic arsenal, these members of the
Enterobacteriaceae family have researchers scrambling for a leg up.
One such genus of concern is Klebsiella. All Klebsiella species tend to act as
opportunistic pathogens, typically only infecting individuals who are
immunocompromised or suffering for another chronic illness. They are an
9

incredibly adaptive class of bacteria, being able to survive in both the environment
(water sources, soil, sewage, etc.) as well as the mucosal surfaces of mammals,
including humans. As such, the clinical areas of most concern for Klebsiella infection
are ones such as the urinary, respiratory, or intestinal tracts. This genus’ most
medically famous species, Klebsiella pneumonieae (KP), is the most common cause of
community-acquired bacterial pneumonia, particularly among chronic alcoholics.
When put into perspective of bacterial species causing gram-negative bacteremia,
Klebsiella species are second only to the infamous Escherichia coli. This genus has
begun to exhibit multiple species strains that are increasingly antibiotic-resistant to
many conventional antibiotics due to their production of extended-spectrum 𝛽lactamases that cleave the 𝛽-lactam structure of said antibiotics [10].
Another tenacious genus within the Enterobacteriaceae family that has
caused serious infection in neonates and immunocompromised individuals is
Citrobacter. This genus raises particular concerns due to its member’s ability to
cause infections affecting a patient’s Central Nervous System (CNS) more severely
than simply causing bacteremia or sepsis as other genera do. These bacteria are
typically located in the feces of mammals and can then spread through water, soil,
and even food [9,11]. If infected with a virulent Citrobacter strain, an individual
could develop bacterial meningitis. In 80% of these confirmed cases the disease can
eventually lead to painful and debilitating CNS abscesses. Signs and symptoms of
Citrobacter meningitis or sepsis include temperature instability, irritability,
decreased oral intake, jaundice, vomiting, lethargy, hypotonia, and possibly seizures
[11]. A particular species that contributes to these clinical manifestations is
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Citrobacter freundii (CF), which is virtually always resistant to standard bacterial
antibiotics like ampicillin or cephalosporins, making it very difficult to treat. It
usually takes a varied combination of antibiotics tailored to a specific situation
coupled with surgical draining of CNS abscesses to effectively treat such illness
presented by this species of Citrobacter. Even with these combinations of drugs
and surgery, some physicians have referred to the overall effectiveness of this
treatment as “generally disappointing.” [11]
Another genus of Enterobacteriacae deemed highly important in the realm of
causing serious nosocomial, opportunistic infections is Enterobacter. These bacteria
are a common species that have been linked to serious cases of bacteremia,
endocarditis, osteomyelitis, and multiple other chronic diseases. An exemplary
species of the whole genus, demonstrating their resilience and pathogenicity, is
Enterobacter cloacae (ECL). The species normally resides as commensal microflora
in the intestinal tracts of humans and other animals. As a pathogen, it is able to
create biofilms, secrete cytotoxins, and exhibit multi-drug-resistance. This species is
intrinsically resistant to ampicillin, amoxicillin, first-generation cephalosporins, as
well as cefoxitin. This remarkable resistance is owed to the bacteria’s production of
constitutive Amp C β-lactamase. However, in recent years, clinical isolates have
been found that have the ability to produce carbapenemase, which can render one of
our most powerful antimicrobial drugs useless in treating an infection [12].
As stated earlier, all of these genera mentioned exhibit powerful antibiotic
resistance that makes treatment of associated infections highly complicated. The
most concerning development in recent years, as mentioned briefly with ECL, is that
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some genera of Enterobacteriaceae have developed adaptations against our
“antibiotic of last resort”: Carbapenems [12]. Every genus mentioned above, not just
Enterobacter, includes certain species that can produce strains exhibiting this new
adaptation of defense. These species make up the classification of Carbapenem
Resistant Enterobacteriaceae (CRE). When the first beta lactamases were
developed by bacteria to combat penicillin in the 1960s, carbapenems were created
as humanity’s counter [13]. It is a member of the antimicrobial class of 𝛽-lactams
and possesses the broadest spectrum of efficacy against both gram-positive and
gram-negative bacteria [13]. Carbapenems attack bacteria by entering through
their outer membrane proteins and inhibiting the enzymes within the cell
responsible for peptidoglycan production via penicillin binding proteins (PBPs).
This ultimately results in the weakening and eventual lysis of the cell’s protective
structure, leading to cell death [13]. Carbapenemases are 𝛽-lactamases that CRE can
produce specifically to attack the structure of the antibiotic before it ever reaches
the PBPs, rendering it useless. There are also other methods, such as efflux pumps
and gene mutations that some bacteria can utilize to also prevent carbapenems from
performing their function [13]. The best treatments we have for bacterial infections
exhibiting such resistance are combination antibiotics, monotherapies, or returning
to previously-thought obsolete drugs, such as colistin. At this point, there is no
single treatment option that is superiorly effective against CRE [14].

Secondary Metabolites
It has been mentioned previously that bacteria have multiple mechanisms for
interacting with one another. These interactions can be either cooperative or
12

hostile depending on the situations and the interactive tendencies of the particular
bacteria involved. What was not directly mentioned, however, were the actual
agents responsible for these interactions. The integral agents of the microbial
community responsible for these cell-to-cell interactions can simply be referred to
as secondary metabolites (SMs).
SMs can be defined as cellular products that do not play an essential role in
growth, development, or reproduction of the producing organism. These
metabolites are often bioactive compounds and can perform important functions in
bacterial defense, competition, signaling, and ecological interactions [15]. These
products are not found among bacteria that are still in their primary growth phase
(trophophase), but are produced when bacteria enter their subsequent production
phase (idiophase) [16]. SM production is typically brought on due to a depletion or
exhaustion of an essential nutrient (such as Carbon), the presence of some other
inducer, or simply a decrease in growth rate [16,17]. The secondary metabolites are
typically produced by modifying primary metabolite synthases that ultimately result
in primarily amino acid derivatives that can be used for a wide variety of functions
[16,18]. Antibiotics, toxins, pheromones, and even the auto-inducers mentioned
above in relation to quorum sensing are all examples of SMs [17].
Clinically, the ability of SMs to have antibiotic properties is the most
significant as far as humans are concerned. Infection-preventing antibiotics such as
bacitracin or erythromycin are both derived from SMs made by some bacteria with
the original purpose to be used against other bacteria [18]. This method of using
bacteria’s own weapons against them has been the foundation of modern bacterial
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infection treatment since Fleming’s ingenuity resulting in penicillin. Ultimately, this
foundation is all possible due to bacteria’s own adaptations for self-preservation
against other microbes. The antimicrobial SMs produced can react to other bacteria
by inhibiting their growth, which in turn allows the bacteria secreting them more
nutrients in their environment. Another possibility, for some, is simply killing rival
bacteria outright to achieve the same effect [19,20]. These two methods of
microbial warfare are, as such, classified as bacteriostatic (inhibiting) or bactericidal
(killing) actions [19].

The current experiment utilizes all of the above information in an effort to
determine the effect and efficacy of a currently unknown product secreted by KP.
We believe it is likely a SM considering its characteristics of what appears to be
competitive inhibition on CF and ECL biofilm formation. Both of these bacterial
species have exhibited multiple drug resistance (MDR) to traditional treatments,
and as such, new methods of treatment are in demand. This product has been found
to be present in the filtered, cell-free spent media from a KP broth culture and
appears to produce similar effects in inhibiting these species in this form as it is
directly secreted from living cells. Both stages of biofilm attachment and maturation
for the two species in question are analyzed when introduced to the filtered KP
liquid containing the unknown product. Multiple assays were performed in order to
determine optical density, mass, and cell viability of the biofilms produced.
Hopefully, with the data and scientific deduction from these trials, a new method of
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treating biofilms produced by the growing threat of MDR Enterobacteriaceae may
emerge.

Materials and Methods
Strains and Media
Klebsiella pneumoniae (ATCC#13883), Citrobacter freundii (ATCC#8090), and
Enterobacter cloacae (ATCC#23355) stocks were purchased from the American
Type Culture Collection. Luria broth (LB), both as a broth and an agar medium, was
used to propagate bacterial strains. When necessary, Carbenicillin (10 𝜇𝑔/mL) was
added to media for the selection of K. pneumoniae.

Preparation of Cell-Free Spent Media
Fresh overnight cultures of KP were used to acquire the inhibitory molecule
of interest. Briefly, 5 mL overnight cultures were pelleted by centrifugation and the
resulting supernatant was further purified via a 0.22-micron syringe filter. The
filtered supernatant was then combined in equal portions with the LB broth and
immediately used for biofilm assays.

Zones of Inhibition
To determine an average zone of inhibition (ZOI) for the unknown secreted
molecule from KP, overnight cultures of bacteria (LB broth, 37℃) of CF and ECL
were used to create bacterial lawns on LB agar plates. 15 𝜇𝐿 of overnight KP culture,
KP cell-free supernatant, or varying concentrations of Ampicillin were spotted onto
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the lawns. Plates were incubated at 37℃ for 24 hours and zones of inhibition
(millimeters) were measured.

Biofilm Formation
In order to produce biofilms for the experiment, overnight cultures of CF and
ECL were adjusted to an 𝑂𝐷!"" reading of 0.01 (~1 x 10! cells/mL) in LB broth and
seeded into a 96 well microtiter plate. For experiments involving the attachment
phase, CF and ECL were seeded either into wells with LB broth or a combination of
equal parts LB and KP cell-free spent media. LB (no bacteria) only wells served as a
control for background. The 96 well plates were then covered with parafilm and
incubated at 37℃ for 24h. For experiments involving the maturation phase, CF and
ECL were seeded (~1x106cells/mL) into the wells with half the amount of LB broth
and incubated for 4h at 37℃. After this short incubation to establish bacterial
biofilms, fresh LB or KP cell free spent media was added accordingly to control and
experimental wells. The 96 well plates were covered with parafilm, and incubated
an additional 24h at 37℃.

Assessing Biofilm Cell Density, Biofilm Mass, and Bacterial Metabolism
Biofilm characteristics were assessed by UV/VIS spectral readings using a
GENESYS 10S or Thermo Fisher Multiskan microtiter plate spectrophotometer. Each
biofilm assay was done in triplicate with each of the three trials having multiple
replicated independent samples.
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Biofilm Cell Density Assay
After incubation, bacterial biofilms were dislodged from wells and optical
density (𝑂𝐷!"" ) was determined. A well containing LB broth only was used as a
blank.

Biofilm Mass Assay
The dye crystal violet (CV) was used to assess biofilm mass. Briefly, the liquid
portion of the biofilm was removed from each well and wells were washed once
with 1X PBS. A 0.1% CV solution was added and incubated at room temperature for
ten minutes. The dye was then pipetted off and wells were again washed with 1X
PBS and the remaining dye within the biofilm cells was released using 33% acetic
acid. Spectrophotometer readings (OD595) were used to assess the amount of
released dye.

Biofilm Cell Metabolism Assay
For determining cell viability, this experiment incorporated the use of an
MTT assay. Briefly, the yellow colored MTT is reduced to its insoluble formazan,
yielding a purple color if the cells were actively metabolizing. To do this, MTT
(5mg/mL) was added to the 96-well plate and incubated at 37℃ for thirty minutes.
Acidic isopropanol was added to resolubilize excess MTT. Spectrophotometer
readings (𝑂𝐷!"# ) were used to assess the amount of reduced MTT.
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Biofilm Viability
Standard plating and dilution methods were used to determine colonyforming units (CFU) of the biofilms. Wells were serially diluted and plated on LB
agar plates, incubated at 37℃ for 24h, and enumerated the next day.

Results and Discussion
Inhibition of CF and ECL Biofilm Attachment
Preliminary studies investigating the KP molecule’s effect on planktonic
culture has shown definitive inhibition of CF and ECL growth in culture. Taking this
information into consideration we first tested the ability of this molecule to inhibit
the beginning stages of biofilm development, the attachment stage. Early biofilm
attachment was assessed for cell density (optical density), biofilm mass (crystal
violet staining), and biofilm cell viability (MTT and CFU enumeration). The 96 well
microtiter plates were uniformly inoculated with the same amount of CF or ECL
(~1x106 cells/mL) with LB alone or equal amounts of LB and KP cell free spent
media. Each of the plates could then be assessed for the four different assays at once
(Figure 1A).
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Controls for each assay consisted of LB only wells containing no bacteria.
There was a visible decrease in turbidity between the control and experimental
wells. Optical density readings were consistent over the three independent trials
and showed a 62% decrease for CF biofilms treated with the KP molecule and a 68%
decrease in ECL-treated biofilms (Figure 2A/2B). However, thanks to our additional
row of wells containing nothing but LB broth, we were able to determine that there
was bacterial biofilm development in all wells. This indicates that, at the point of
biofilm attachment, the uncharacterized product from KP is inhibitory to
attachment and eventual production but is unable to fully prevent attachment of
19

bacteria. It is important to note that we have thus far not been able to isolate and
purify the molecule of interest and so the cell free spent media contains very dilute
amounts of the molecule. It is possible that upon isolation and purification of the
molecule that a completely inhibitory effect, in regards to attachment, could be
possible. Figure 1A shows the microtiter assay plate at the conclusion of all
performed assays. Dilution plates for CF (Figure 1B) and ECL (Figure 1C) were also
compared to further illustrate the inhibition of both bacteria.
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1B

For assessment of biofilm mass, CV was used to stain attached

1C

cells on the 96 well plates. Cells that take up the CV stain are lysed, releasing the
dye, and mass can be calculated as a proportion by absorbance at OD595. When CF
was treated with the KP molecule there was a 73% reduction in biofilm mass in
comparison to the CF untreated control (Figure 3A/3B). The KP molecule appears to
have had an even more prominent reduction of 85% on ECL biofilm mass during
attachment phases (Figure 3A/3B). We believe this to be indicative of a major
reduction in biofilm mass due to the inhibitory actions of the uncharacterized
molecule.
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The OD and CV assays only express cells in terms of amount of cells, but are
unable to indicate whether those cells are, in fact, alive or dead. To determine if
there was a reduction in cell viability we implemented an MTT assay. In this assay
the yellow MTT is reduced to a purple formazan product by actively metabolizing
bacterial cells. Thus, the amount of reduced product can be determined by
spectrophotometer readings (OD570) and the proportion of cells that are viable can
be calculated. There was a reduction in both CF and ECL cell viability, though this
reduction was not as drastic, as compared to the other OD and CV reductions. CF
exhibited a 52% reduction in viable cells between control and experimental wells
while ECL revealed a substantially greater 71% reduction between its two
conditions (Figure 4A/4B). As such, for both CF and ECL at the attachment stage of
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biofilm formation, there is a quantifiable decrease in viable cells present in the
cultures.

Inhibition of CF and ECL Biofilm Maturation
We then tested the ability of this molecule to inhibit early-stages of
maturation, when the biofilms are forming, but not fully mature yet. Similarly to
attachment, biofilm maturation was assessed for cell density (optical density),
biofilm mass (crystal violet staining), and biofilm cell viability (MTT and CFU
enumeration). The 96 well microtiter plates were uniformly inoculated with the
same amount of CF or ECL (~1x106 cells/mL) and half the amount in each well of LB
alone (100 𝜇𝐿). This plate was placed in the 37℃ incubator for a total of 4 hours.
After this span of time, the remaining amounts of LB broth or KP product were
added to their respective wells. Each of the plates were assessed for the four
different assays at once, shown in Figure 5A.
Controls for each assay were comprised of wells filled with only LB and no
bacteria. There was a visible decrease in turbidity between the control and
experimental wells. Optical density readings were consistent over the three
independent trials and showed a 56% decrease for CF biofilms treated with the KP
molecule and a 65% decrease in ECL treated biofilms (Figure 6A/6B). Both of these
values were only slightly (<~7%) less than what we found for the attachment series,
indicating a slight lessening in effectiveness of the molecule at inhibiting biofilm
formation at the maturation stage.
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Due to this experimental series focusing on the biofilm phase of maturation,
it was expected that we would see biofilm growth in all wells except our LB only
wells. This fact reinforces that, at the dilutions used for this experiment, the KP
product in question possesses bacteriostatic rather than bactericidal effects due to
pre-formed biofilms still being present, yet inhibited from the point of KP product
addition onward. Figure 5A shows the microtiter assay plate at the conclusion of all
performed assays. Dilution plates for CF (Figure 5B) and ECL (Figure 5C) were also
compared to further illustrate the inhibition of both bacteria.
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The same method of using CV to stain attached cells on the 96 well plates
that was used for the attachment phase was used in the maturation trials. The mass
can be calculated as a proportion by absorbance at OD595, as before. For this series,
when CF was treated with the KP molecule there was a 89% reduction in biofilm
mass in comparison to the CF untreated control, demonstrating what appears to be
superior action of the KP molecule when compared with the attachment data
(Figure 7A/7B). Contrarily, ECL only exhibited an average reduction of 71% in
biofilm mass when added 4 hours after incubation began, which is >10% less
effective than when the filtrate was introduced immediately (Figure 7A/7B).
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To determine if the cells present were alive or dead, an MTT assay was
utilized. The amount of reduced product was determined by spectrophotometer
readings (OD570) and the proportion of cells that are viable was then calculated.
61% average viable cell reduction was found between the control and experimental
categories for CF, which is ~8% greater efficacy than when the KP molecule was
added to inhibit the attachment phase of biofilm formation (Figure 8A/8B).
Inversely, the ECL averages indicated a 60% reduction of viable cells due to the
filtrate’s addition at the maturation stage which is >10% less efficacy than when it
was added for attachment (Figure 8A/8B). For both CF and ECL at the maturation
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stage of biofilm formation, we can conclude that there is a similar quantifiable
decrease in viable cells present in the cultures read by the spectrophotometer
(𝑂𝐷!"# ) as compared to the attachment stage trails.

Determination of KP molecule Zones of Inhibition (ZOI)
Lastly, it was determined from the data that the unknown molecule secreted
from KP has the capability to create a ZOI that closely resembles the same action
enacted by lower concentrations of the antibiotic Ampicillin on lawns of CF and ECL.
In too low dilutions, the antibiotic won’t create any ZOI of CF lawns (Figure 9A/9B).
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However, the filtrate is capable of creating a ZOI very similar to what would be
produced if the KP cells were placed on the lawn. With ECL, which appears to be
more susceptible to Ampicillin than CF, the KP filtrate proved to be slightly less
effective than the lowest antibiotic dilution we tested, but more effective than the
KP cell trial.
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Conclusions
The results of this study are indicative of the uncharacterized KP molecule
possessing inhibitory effects on CF and ECL biofilm formation at both stages of
attachment and maturation at the dilutions used. For each condition tested, there
was substantial reduction by more than 50% between control groups and those
exposed to the uncharacterized product. This shows that the molecule in question
has inhibitory effects on the bacteria’s biofilm cell density, mass, and cell viability,
ultimately weakening these bacteria’s biofilms.
The mechanism of how exactly this molecule does this, as well as what
exactly this product from KP is categorized as, is still in question. We are not certain
if this product exhibits strictly bacteriostatic effects or if there is possibility for more
dramatic, bactericidal action upon purification. Again, only the liquid, dilute form of
this product was used for this study, and the behavior of the KP product in higher
concentrations with higher concentrations of bacteria remains to be tested.
The future goals of this series of experiments would include the isolation,
identification, and successful purification of this unknown product secreted by KP
so that the full extent of its antimicrobial effects could then be analyzed. At present,
the results of this study are highly optimistic for multiple practical applications of
the product in question. There is the possibility of alternative solutions to CF and
ECL infections rather than traditional, high-dose antibiotics. Should an infection
develop biofilms and run the risk of becoming a chronic illness in a patient, we now
have an antimicrobial agent that may be capable of treating MDR CF and ECL, giving
medicine a new weapon in microbial warfare.
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